for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Getinge AB

GETIb.ST

Latest Trade

160.50SEK

Change

3.45(+2.20%)

Volume

4,802,001

Today's Range

158.15

 - 

166.10

52 Week Range

76.92

 - 

166.10

As of on the Stockholm Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Getinge Q3 Adjusted EBITA Up At SEK 677 Million

Oct 18 (Reuters) - Getinge AB <GETIb.ST>::Q3 2019 RESULT: CONTINUED GROWTH AND IMPROVED MARGINS.JULY-SEPT ADJUSTED EBITA AMOUNTED TO SEK 677 M (438).Q3 NET SALES SEK 6,236 MILLION (REFINITIV POLL: SEK 6,074 MILLION).OUTLOOK 2019: ORGANIC SALES GROWTH SEEN TO BE 2-4% FOR FY 2019."OUR OPERATING EXPENSES WERE SLIGHTLY HIGHER COMPARED WITH Q3 2018, MAINLY DUE TO REMEDIATION MEASURES AND EU MDR PREPARATIONS" CEO.Q3 ORDER INTAKE SEK 6.68 MILLION VERSUS SEK 6.17 BILLION YEAR AGO.

Getinge Informs About A Global Class 1 Recall For Cardiosave IABP And CS100/300

July 18 (Reuters) - Getinge AB <GETIb.ST>::GETINGE - IS INFORMING ABOUT A GLOBAL CLASS 1 RECALL FOR CARDIOSAVE HYBRID, CARDIOSAVE RESCUE, CS300 AND CS100 INTRA-AORTIC BALLOON PUMPS (IABP).GETINGE - REPORTED RECALL FOR CARDIOSAVE IABP & CS100/300 TO RELEVANT AUTHORITIES ACCORDING TO APPLICABLE REGULATIONS & COST FOR RECALL IS NOT MATERIAL.

Getinge April-June Adjusted EBITA Up At SEK 591 Million

July 17 (Reuters) - Getinge AB <GETIb.ST>::PUBLISHES INTERIM REPORT FOR JANUARY - JUNE 2019.APRIL-JUNE NET SALES INCREASED ORGANICALLY BY 4.0% AND ORDER INTAKE ROSE BY 5.2%.APRIL-JUNE ADJUSTED EBITA AMOUNTED TO SEK 591 M (538).OUTLOOK 2019 ORGANIC SALE GROWTH IS EXPECTED TO BE 2-4% FOR THE FULL-YEAR 2019.APRIL-JUNE ADJUSTED GROSS PROFIT AMOUNTED TO SEK 3,101 M (2,844).

Hanza Expands Cooperation With Getinge

April 8 (Reuters) - Hanza AB <HANZA.ST>::EXPANDS COOPERATION WITH GETINGE.NEW DEAL HAS YEARLY VALUE OF ABOUT SEK 20 MILLION.PRODUCTION TO START IMMEDIATELY AND TO BE FULLY OPERATIONAL IN LAST QUARTER OF 2019.

Getinge says Johan Malmquist proposed as new chairman of board

Dec 10 (Reuters) - Getinge AB <GETIb.ST>::JOHAN MALMQUIST PROPOSED AS NEW CHAIRMAN OF BOARD FOR GETINGE AB.CARL BENNET WILL CONTINUE AS MEMBER OF BOARD AND IS PROPOSED AS VICE CHAIRMAN OF BOARD.

Getinge issues voluntary medical device recall for the QUADROX‐i Neonatal Oxygenator

Nov 26 (Reuters) - Getinge AB <GETIb.ST>::INFORMS ABOUT VOLUNTARY RECALL OF QUADROX-I NEONATAL OXYGENATOR.SAYS HAS REPORTED TO RELEVANT COMPETENT AUTHORITIES ACCORDING TO APPLICABLE REGULATIONS AND DOES NOT EXPECT THE COST FOR THE RECALL TO BE MATERIAL.SAYS TO DATE, THERE ARE NO KNOWN ADVERSE EVENTS ASSOCIATED WITH SERIOUS INJURY OR DEATH.SAYS THE RECALL CONCERNS AN ENCLOSED ADAPTER TO THE DEVICE, WHICH CAN CAUSE BLOOD LEAKAGE AT THE BLOOD INLET CONNECTOR.SAYS IN TOTAL 22,749 UNITS OF QUADROX-I NEONATAL HAVE BEEN DISTRIBUTED GLOBALLY BETWEEN OCTOBER, 2016 AND OCTOBER 2018. THE ADAPTER IS USED IN 10% OF THE THERAPY CASES. IN THE US, THE RECALL AFFECTS 9 CUSTOMERS, AND HAS BEEN CLASSIFIED AS A CLASS I RECALL BY THE FDA.SAYS SINCE DECEMBER 2017 THE PRODUCT IS NO LONGER DISTRIBUTED TO THE US MARKET .

FDA Says Maquet Datascope Corp/Getinge Group Recalls Cardiosave Hybrid & Cardiosave Rescue Intra-Aortic Balloon Pumps

Nov 1 (Reuters) - Getinge AB <GETIb.ST>::FDA SAYS MAQUET DATASCOPE CORP/GETINGE GROUP RECALLS CARDIOSAVE HYBRID & CARDIOSAVE RESCUE INTRA-AORTIC BALLOON PUMPS.FDA - RECALL OF CARDIOSAVE HYBRID & CARDIOSAVE RESCUE IABPS DUE TO POTENTIAL OF AUTOFILL PROCESS TO MALFUNCTION OR FAIL DURING USE AT HIGH ALTITUDES.FDA - IDENTIFIED RECALL OF CARDIOSAVE HYBRID & CARDIOSAVE RESCUE IABPS AS A CLASS I RECALL.

Getinge Q1 operating result lags forecast

April 26 (Reuters) - Getinge AB <GETIb.ST>::Q1 ADJUSTED EBITA AMOUNTED TO SEK 301 M (485).Q1 ORDER INTAKE INCREASED ORGANICALLY BY 3.1%.Q1 NET SALES INCREASED ORGANICALLY BY 5.4%.Q1 OPERATING PROFIT (EBIT) AMOUNTED TO SEK -161 M (302), CURRENCY EFFECTS HAD A NEGATIVE IMPACT OF SEK -115 M ON EBIT.SAYS ORGANIC SALES GROWTH IS EXPECTED TO BE SLIGHTLY POSITIVE IN 2018.SAYS CURRENCY TRANSACTION EFFECTS ARE EXPECTED TO HAVE A NEGATIVE IMPACT OF APPROXIMATELY SEK -150 M (-100) ON THE GROUP’S 2018 EBIT.Q1 ORDER INTAKE 5,328 MILLION SEK.REUTERS POLL: GETINGE Q1 ORDER INTAKE WAS SEEN AT 5.4 BILLION SEK, OPERATING RESULT AT -62 MILLION.

Getinge Makes 350 Mln SEK Additional Provisions

March 21 (Reuters) - Getinge <GETIb.ST>::MAKES ADDITIONAL PROVISIONS OF 350 MILLION SWEDISH CROWNS ($42.63 MILLION) IN RELATION TO BRAZILIAN INVESTIGATIONS.SAYS ‍TO MAKE AN ADDITIONAL PROVISON OF MSEK 350 RELATED TO, AMONG OTHER THINGS, ALLEGED FRAUD IN BIDDING PROCEEDINGS IN BRAZIL MAINLY ATTRIBUTABLE TO YEARS 2004-2015​.SAYS ‍ADDITIONAL PROVISION WILL HAVE EFFECT ON OPERATING PROFIT OF Q1 2018​.SAYS ‍NEGOTIATIONS WILL CONTINUE WITH RELEVANT AUTHORITIES AND ARE EXPECTED TO BE FINALIZED DURING 2018​.SAYS ‍IT CANNOT BE EXCLUDED THAT SETTLEMENTS WITH RELEVANT AUTHORITIES WILL HAVE ADDITIONAL SIGNIFICANT EFFECT ON RESULT AND FINANCIAL POSITION OF GETINGE​.SAYS PROVISIONS ‍PRIMARILY RELATED TO GETINGE'S BRAZILIAN SUBSIDIARIES MAQUET CARDIOPULMONARY DO BRASIL INDÚSTRIA E COMÉRCIO LTDA AND MAQUET DO BRASIL EQUIPAMENTOS MÉDICOS LTDA​.

Getinge Q4 core profit far below forecast​

Jan 29 (Reuters) - Getinge <GETIb.ST>::Q4 ‍ORDER INTAKE INCREASED BY 2.3% TO SEK 6,624 M (6,473)​.Q4 ‍ORDER INTAKE INCREASED ORGANICALLY BY 6.6%​.Q4 ‍NET SALES FELL BY 0.8% TO SEK 7,371 M (7,434)​.Q4 ‍EBITA 1** AMOUNTED TO SEK 1,111 M (1,689) WITH AN EBITA 1 MARGIN OF 15.1% (22.7)​.Q4 ‍EXCLUDING NON-RECURRING ITEMS, EBITA 1 AMOUNTED TO SEK 1,377 M (1,484) AND EBITA 1 MARGIN TO 18.7% (20.0)​.SAYS ‍A DIVIDEND PER SHARE OF SEK 1.50 (1.75***) IS PROPOSED, CORRESPONDING TO SEK 409 M (477).REUTERS POLL: GETINGE Q4 ORDER INTAKE WAS SEEN AT 6.5 BILLION SEK, ADJUSTED. EBITA AT 1.6 BILLION, DIVIDEND AT 1.76 SEK/SHARE​.OUTLOOK 2018: ORGANIC SALES GROWTH IS EXPECTED TO BE SLIGHTLY POSITIVE IN 2018​.OUTLOOK 2018: CURRENCY TRANSACTION EFFECTS ARE EXPECTED TO HAVE A NEGATIVE IMPACT OF APPROXIMATELY SEK 100 M ON THE GROUP’S 2018 EBIT.SAYS EXCLUDING NON-RECURRING ITEMS, GROSS PROFIT WAS IN LINE WITH THE YEAR-EARLIER PERIOD, WHILE EBITA 1 WAS NOT SATISFACTORY.OPERATING PROFIT WAS NEGATIVELY AFFECTED BY OUTSTANDING GROUP-WIDE EXPENSES FOLLOWING THE DISTRIBUTION OF ARJO.SAYS WE ARE TACKLING THIS BY GRADUALLY REDUCING OUR OPERATING EXPENSES IN RELATION TO SALES.SAYS NON-RECURRING COSTS CHARGED TO GROSS PROFIT FOR THE QUARTER PRIMARILY COMPRISE WRITE-DOWNS OF A NUMBER OF CAPITALIZED RESEARCH PROJECTS AND INVENTORY IMPAIRMENT. ​.SAYS THE REMEDIATION PROGRAM RELATED TO THE CONSENT DECREE WITH FDA CONTINUED ACCORDING TO PLAN AT ALL UNITS CONCERNED DURING THE FOURTH QUARTER.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up